Results of high-risk neutropenia therapy of hematology–oncology patients in a university hospital in Uruguay  by Boada Burutaran, Matilde et al.
rev bras hematol hemoter. 2 0 1 5;3 7(1):28–33
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
www.rbhh.org
Original article
Results  of  high-risk  neutropenia  therapy  of
hematology–oncology patients  in a university
hospital in Uruguay
Matilde Boada Burutaran ∗,1, Regina Guadagna1, Soﬁa Grille1, Mariana Stevenazzi,
Cecilia  Guillermo, Lilian Diaz
Universidad de la República, Montevideo, Uruguay
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 5 May 2014
Accepted 9 July 2014
Available online 21 November 2014
Keywords:
Neutropenia
Clinical protocols
Hematologic diseases
Gram-negative bacterial infections
Drug resistance, bacterial
a  b  s  t  r  a  c  t
Background: Febrile neutropenia is an important cause of mortality and morbidity in
hematology–oncology patients undergoing chemotherapy. The management of febrile neu-
tropenia is typically algorithm-driven. The aim of this study was to assess the results of a
standardized protocol for the treatment of febrile neutropenia.
Methods: A retrospective cohort study (2011–2012) was conducted of patients with high-risk
neutropenia in a hematology–oncology service.
Results: Forty-four episodes of 17 patients with a median age of 48 years (range: 18–78 years)
were  included. The incidence of febrile neutropenia was 61.4%. The presence of febrile neu-
tropenia was associated with both the duration and severity of neutropenia. Microbiological
agents were isolated from different sources in 59.3% of the episodes with bacteremia iso-
lated from blood being the most prevalent (81.3%). Multiple drug-resistant gram-negative
bacilli were isolated in 62.5% of all microbiologically documented infections. Treatment of
63%  of the episodes in which the initial treatment was piperacillin/tazobactam needed to be
escalated to meropenem. The mortality rate due to febrile neutropenia episodes was 18.5%.
Conclusion: The high rate of gram-negative bacilli resistant to piperacillin/tazobactam (front-
line  antibiotics in our protocol) and the early need to escalate to carbapenems raises the
question as to whether it is necessary to change the current protocol.©  2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. PublishedIntroductionFebrile neutropenia (FN) is among the leading causes of
mortality and morbidity in hematology-oncologic patients
∗ Corresponding author at: Hospital de Clínicas, Facultad de Medicina, 
Uruguay.
E-mail  address: matilde boada@hotmail.com (M. Boada Burutaran).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.bjhh.2014.11.012
1516-8484/© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia
reserved.by Elsevier Editora Ltda. All rights reserved.
undergoing intensive cytotoxic chemotherapy. It implies a
large economic and social burden on the health system1,2 as itUniversidad de la República, Av. Italia s.n., CP 11600 Montevideo,
represents the most frequent complication in these patients.3
Infectious complications are the main cause of death not
related to cancer progression.
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
oter. 
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The incidence of FN was reported in around 10–50% of
atients with solid tumors and up to 80% of those with
ematologic malignancies.4 In the pre-empiric antibiotics era,
ortality due to infectious complications in patients receiv-
ng intensive chemotherapy was as high as 70%.5 Nowadays,
his ﬁgure has dropped to between 1% and 18%,4,6,7 but still
epresents a serious problem that must be addressed actively
sing a multidisciplinary approach.
FN is a potentially life-threatening situation that requires
rompt medical intervention. As neutropenic patients have
n impaired inﬂammatory response, infection can occur
ith minimal signs and symptoms and progress rapidly,
volving with hypotension, renal failure, acidosis, or other
ife-threatening complications that lead to sepsis with mul-
iorgan failure.2 As fever may constitute the isolated sign in
hese patients, it should be considered a real emergency. Early
ecognition of FN is critical to initiate broad-spectrum, empiric
ystemic antibacterial therapy promptly in order to avoid pro-
ression to sepsis and possible death.8
The prophylactic use of granulocyte colony-stimulating
actor (G-CSF) to reduce the incidence of FN, as well as to
nhance antibiotic therapy, has been widely studied in the
ast few years with conﬂicting results.9 In 2004 a Cochrane
ollaboration review concluded that the use of growth factors
ombined with antibiotic therapy in established FN caused
y chemotherapy reduced the hospital stay and the duration
f neutropenia, but the overall mortality was not inﬂuenced
igniﬁcantly.9 Furthermore, a meta-analysis in 2011 concluded
hat the use of G-CSF as primary prophylaxis reduced the
ncidence of FN in patients receiving chemotherapy for solid
umors and lymphoma.10
The management of FN is typically algorithm-driven. The
ffectiveness of the antibacterial protocol proposed by inter-
ational guidelines to reduce FN-related mortality has already
een reported.4,7 Thus, the aim of this study was to assess
he impact of the implementation of international recom-
endations as the standardized protocol of local guidelines
n 2011.11 One of the speciﬁc objectives of this study was to
ssess whether the protocol was correctly followed in each
ase.
ethods
his is an analytic observational, retrospective, cohort study
onducted from July 2011 to August 2012. The data were col-
ected from the medical charts preserving the conﬁdentiality
f each patient.
atients
he inclusion criteria were patients older than 18 years, under-
oing intensive chemotherapy in the Hematology–oncology
epartment of the Hospital de clínicas Dr. Manuel Quintelan Montevideo, Uruguay, for whom high-risk neutropenia was
xpected. Patients treated in this service that, because of their
ersonal risk factors and comorbidities, suffered high-risk
eutropenia but did not receive intensive chemotherapy were
xcluded.2 0 1 5;3 7(1):28–33 29
Deﬁnitions
Intensive chemotherapy was deﬁned as chemotherapy regi-
mens that cause high-risk neutropenia such as those used
to treat acute myeloid leukemia, acute lymphoid leukemia,
Burkitt lymphoma, and second lines for Hodgkin’s and Non-
Hodgkin’s lymphoma. High-risk neutropenia was deﬁned as
one that is expected to last more  than seven days.
Neutropenia was deﬁned as a neutrophil count under
0.5 × 109/L or under 1.0 × 109/L when it was expected to reach
under 0.5 × 109/L within the following 48 h. Severe neutropenia
was deﬁned as a neutrophil count under 0.1 × 109/L. Patients
diagnosed with acute leukemia were considered to have func-
tional neutropenia even though they had neutrophil counts
above 1.0 × 109/L. Fever was deﬁned as an oral temperature
above 38 ◦C or a persistent temperature above 37.8 ◦C.
Alarm signs were deﬁned in the protocol as the presence
of at least one of the following: heart rate above 100 beats per
minute, respiratory frequency above 20 breaths per minute,
low carbon dioxide under 35 mmHg, oxygen under 100 mmHg
or oxygen saturation under 93% while receiving supplemen-
tary oxygen, capillary reﬁll longer than eight seconds, low pH,
base excess under 5 meq/L, serum lactate above 2 mmol/L, sys-
tolic blood pressure under 90 mmHg, confusion, or oliguria.
Clinical  and  laboratory  studies
When a febrile episode was diagnosed, a detailed physical
examination was made and repeated daily. Additionally, sam-
ples of blood, and urine and samples from other suspected
infection sites were taken before the initiation of empiri-
cal antibiotic treatment. If the patient had a central venous
catheter, at least one blood culture was prepared for each
lumen of the catheter and one of a peripheral vein. A chest
radiograph was obtained and urinalysis performed within the
ﬁrst 24 h. Computed tomographies (CT) of the lung, head,
sinuses, abdomen, and pelvis were performed as clinically
indicated. Routine hematological investigations and biochem-
ical analysis were carried out before treatment was started and
every three days thereafter during the course of the therapy.
Additionally, C-reactive protein and procalcitonin levels
were determined. A sinus and lung CT and serial galactoman-
nan antigen test were performed prior to the initiation of
antifungal therapy when a fungal infection was suspected
in patients who remained febrile after 6–7 days of broad-
spectrum antibiotic treatment.
Antibiotic  treatment  protocol
The protocol consisted in the use of a broad-spectrum antimi-
crobial (Figure 1).11 Piperacillin–tazobactam therapy (4.5 g
every 6 h) was started in patients without one of the following:
alarm signs, more  than one week of hospital stay, or having
received ciproﬂoxacin or third-generation cephalosporin as
prophylaxis within the previous 30 days. The other patients
received meropenem (1 g every 8 h). Prophylactic antiviral (acy-
clovir) and antifungal (ﬂuconazole) medications were given in
all cases.
The initial empirical treatment was modiﬁed by chang-
ing the medication to meropenem, if there was: (a)
30  rev bras hematol hemote
Febril Neutropenia
Low risk
Out-patient care
High risk
Admission
- Alarm signs
- Admission > 1week
- Previous ciprofloxacin or 3rd
generation cephalosporin in last 30
days
No
Piperazilin/tazobactam
Yes
Meropenem
(Vancomicin in selected
cases)Figure 1 – Protocol-based algorithm in the management of
febrile neutropenia.deterioration in the clinical state after 24 h, (b) alarm
signs, hemodynamic instability or other organ dysfunc-
tion, (c) fever persistence after four days of treatment, (d)
culture with antibiotic-resistant organism (particularly
Table 1 – Patients’ characteristic.
Febrile episodes 
Episodes – n (%) 27 (61.4) 
Age – median (range) years 43 
Gender – female:male 1.0:1.0 
Febrile days – median ± SD 4.5 ± 4.4 
Neutropenia – median ± SD (days) 16.1 ± 8
Severe neutropenia – median ± SD (days) 7.8 ± 5.3
Hematology–oncology diagnosis n (%
AML/myelodysplastic syndromes 18 66
Acute lymphoid leukemia 2 7
Non-Hodgkin’s lymphoma 7 25
Hodgkin’s lymphoma 0 0
Chemotherapy regimen n (%
High-dose cytarabine (HIDAC) 6 24
Cytarabine–Daunorubicin (7 + 3) 8 32
CODOX-M 4 16
IVAC 1 4
FLAG 2 8
ESHAP 0 0
MINI BEAM 0 0
Berlin–Frankfurt–Munich (BFM) 2008 protocol 1 4
Hyper-CVAD 1 4
IVE 1 4
HIDAC + Daunorubicin 1 4
AML: Acute myeloid leukemia; CODOX-M: cyclophosphamide, vincristine, d
and high-dose cytarabine; FLAG: ﬂudarabine, cytarabine, and ﬁlgrastim; ES
BEAM: carmustine, etoposide, cytarabine, and melphalan; Hyper-CVAD: cy
ifosfamide, vincristine, and etoposider. 2 0 1 5;3 7(1):28–33
methicillin-resistant Staphylococcus aureus [MRSA] or
extended-spectrum b-lactamase [ESBL]-producing gram-
negative bacteria). In patients with hemodynamic instability,
skin or soft tissue infection, suspected catheter-related infec-
tion or MRSA culture positive, vancomycin was added (1 g
every 12 h). Vancomycin was stopped after two  days if there
was  no evidence of gram-positive infection. Documented
clinical and/or microbiological infections were treated with
antibiotics appropriate for the site and susceptibility of
each isolated organism. Empirical antifungal coverage was
considered in patients who had persistent fever after 6–7 days
of antibiotic treatment without identiﬁed fever source.
Statistical  analysis
Statistical analysis was made using the Statistics Program
for Social Sciences software. The Chi-square test was used
to compare categorical variables and the Mann–Whitney test
for continuous variables. The Odds ratio was calculated. A
p-value < 0.05 was considered statistically signiﬁcant.
ResultsForty-four episodes of high-risk neutropenia (17 patients) with
a median age of 48 years (range: 18–78 years) were included
in this study (Table 1). There was a slight predominance of
females (female:male ratio 1.1:1). The distribution of cancer
Non-febrile episodes Total p-Value
17 (38.6) 44–100 0.49
40.1 48 (18–78) 0.06
0.7:1.0 1.1:1 0.49
4.5 ± 4.4
9  ± 3.8 13.1 ± 7.8 0.001
3.5  ± 3.0 6.2 ± 5.0 0.005
) n (%) n (%)
.6 7 41.2 25 56.8
.5 1 5.9 3 6.8
.9 7 41.2 14 31.9
 2 11.7 2 4.5
) n (%) n (%)
.0 7 41.2 13 29.5
.0 0 0 8 18.2
.0 3 17.6 7 15.9
.0 2 11.8 3 6.8
.0 0 0 2 4.5
.0 2 11.8 2 4.5
.0 2 11.8 2 4.5
.0 1 5.8 2 4.5
.0 0 0 1 2.3
.0 0 0 1 2.3
.0 0 0 1 2.3
oxorubicin, and high-dose methotrexate; IVAC: ifosfamide, etoposide
HAP: etoposide, methylprednisolone, cytarabine, and cisplatin; MINI
clophosphamide, vincristine, doxorubicin, and dexamethasone; IVE:
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Table 3 – Microbiological isolation.
Microbiological agent Relative frequency (%)
Multi-resistant Klebsiella 37.5
Multi-resistant E. coli 25.0
Sensitive E. coli 12.5
Methicillin-resistant Staphylococcus aureus 6.3
Coagulase negative Staphylococcus 6.3
Chriseobacterium indologens 6.3Figure 2 – Days of febrile neutropenia.
ypes and chemotherapy treatment regimens are shown in
able 1. Acute myeloid leukemia (AML) and its treatment were
he most common type of cancer and chemotherapy regimen.
on-Hodgkin’s lymphomas comprising Burkitt’s lymphomas
nine episodes registered in two patients), lymphoblastic lym-
homa (one episode), entheropathy-associated T Lymphoma
one episode), and refractory or relapsed diffuse large cell lym-
homa or T lymphomas (three episodes in two patients) were
bserved.
Of the 44 episodes of high-risk neutropenia, 27 (61.4%)
xperienced fever during neutropenia. Every patient included
n this study experienced FN in at least one of the episodes.
According to the results, FN was signiﬁcantly associated
ith both the duration of neutropenia (p-value = 0.001) with a
edian of nine days for afebrile vs. 16 days for febrile episodes,
nd the duration of severe neutropenia (p-value = 0.005) with
 median of 3.5 days for afebrile compared with 7.8 days for
ebrile episodes (Figure 2). The prophylactic use of ﬁlgrastim
as not standardized in our service and depended on the
hoice of each physician. The use of ﬁlgrastim was associated
ith neither the duration nor the incidence of FN. In 62% ofhe episodes, the site of infection was identiﬁed, either clini-
ally, by imaging techniques, or by microbiological cultures. As
Table 2 – Clinical site of infection.
Clinical site of infection n (%)
Not identiﬁed 23 (52.3%)
Lungs 8 (18.2%)
Skin 3 (6.8%)
Urinary tract 2 (4.5%)
Abdominal 1 (2.3%)
Ear, nose, or throat 1 (2.3%)
Others 1 (2.3%)Mycobacterium tuberculosis 6.3
shown in Table 2, the respiratory tract was the most common
site of infection (41%), followed by the skin and others.
Microbiological cultures were achieved in 59.3% (n = 16) of
the febrile episodes (Table 2). A total of 75% of all isolates
were gram-negative bacilli (GNB). Of the multiple-antibiotic-
resistant (MR) GNB (62.5%), deﬁned as resistance to at least
three different antibiotic groups, six isolates were MR  Klebsiella
pneumoniae (speciﬁcally ESBL K. pneumonia)  and four isolates
were MR  Escherichia coli (ESBL). Regarding the source of the iso-
late (Table 3), 13 were from blood cultures, representing 48% of
bacteremia in all FN episodes and 81.3% of all microbiological
documented infections. All of the MR-GNB were susceptible
to imipenem, meropenem and amikacin and resistant to all
other antibiotic classes, including piperacillin and tazobac-
tam.
When considering only the ﬁrst FN episode of each patient,
microbiological isolates were identiﬁed in 53% of episodes
with 77.7% of these being MR-GNB. For 14 (63%) of the episodes
in which the initial treatment was piperacillin/tazobactam,
therapy needed to be escalated to meropenem in a mean
time of 4.5 ± 2.5 days of treatment. The mortality rate of these
episodes was 28%; 47% had a MR-GNB and 35% had negative
cultures. One patient was diagnosed with pulmonary tubercu-
losis.
The overall mortality rate in all neutropenic episodes was
13.6% (n = 6) and the mortality rate in febrile neutropenic
episodes alone was 18.5%. Three of these patients died due to
sepsis (11.1% of mortality due to sepsis in FN episodes) and the
others due to disease progression. Every death-related infec-
tion was reported in the ﬁrst FN episode. Death occurred in
35% of the episodes in which the microbiological agent was
isolated and there were no deaths in episodes with negative
cultures (p-value = 0.027).
Nine (33%) of the FN episodes presented at least one of the
alarm signs deﬁned in the protocol of this study. The mortal-
ity rate of these was 44% vs. 6% in episodes without alarm
signs (p-value = 0.018). This determines an OR of 13.0 for the
presence of alarm signs.
There were 15 (34.1%) episodes that were treated with
piperacillin–tazobactam as front-line therapy even though
these patients had received prophylaxis with ciproﬂoxacin.
Discussion
Infectious diseases are an important complication in
hematology-oncologic patients resulting in longer hospital
stays, and increased morbidity and mortality. Neutropenia has
been recognized for many  decades as a major risk factor for the
mote32  rev bras hematol he
development of infections in hematology-oncologic patients
undergoing chemotherapy.12
Here, we  present the ﬁrst-year results and features of infec-
tious diseases since the implementation of a new protocol
in the management of FN in high-risk hematology-oncologic
patients at a University Hospital in Uruguay. Before the imple-
mentation of this protocol the management of FN was not
standardized in this service and physicians decided based on
the available evidence, the international guidelines, and their
own personal experience.
The main ﬁndings of this work were the high rate of micro-
biological agents isolated in FN episodes, and the elevated
prevalence of MR-GNB.
Microbiological documented infections were statistically
associated with higher mortality. This ﬁnding can be
explained by the fact that bacteremia was the most frequent
documented infection (81.3%). Teixeira et al. recently reported
that in hematopoietic stem cell transplantation patients,
microbiologically documented infections represented a death
risk factor and that bacteremia was the most commonly doc-
umented infection (46.3%).13 Furthermore, it is known that in
other infectious diseases, such as community-acquired pneu-
mococcal pneumonia, bacteremia is associated with increased
severity and mortality.14
The etiology of infections in FN has varied in the last ﬁfty
years. In the 1970s and early 1980s there was a predominance
of gram-negative microorganisms but in the late 1980s and
in the 1990s there was a dramatic increase in gram-positive
bacteria, with these becoming the most common infecting
organisms.15,16 This led to changes in antibiotic treatments,
focusing on resistant gram-positive strains.17 However, in
the last few years, an increase in GNB has been reported
worldwide.16 This work identiﬁed an important predominance
of GNB  concordant with other recent regional reports.14,15
However, there were more  resistant GNB, particularly ESBL,
than reported in most series.13,15,16
There was an early need to escalate to meropenem in a
high number of episodes, and in many  of them MR-GNB were
isolated.
The mortality rate observed due to sepsis was 23.5% and
this was statistically associated with the isolation of microbi-
ological agents and the presence of at least one alarm sign.
The incidence of FN in our service was similar to oth-
ers reported in the literature.4,6,7 However, the mortality rates
were slightly higher than reported by referral services but sim-
ilar to those reported in other Latin American countries.18,19
The presence of fever was associated with duration and
severity of neutropenia. Historical studies show that as the
neutrophil count drops below 0.5 × 109/L, the susceptibility
to infection increases.20 Moreover, it has been reported that
the frequency and severity of infection are inversely propor-
tional to the neutrophil count. The risk of severe infection
and bacteremia are high when the neutrophil count is less
than 1.0 × 109/L. The rate of decline of the neutrophil count
and the duration of neutropenia are also important factors
to consider.21–23 Additionally, it has been reported that an
increase in the neutrophil count during treatment improves
outcomes. Bodey et al. informed that the mortality rate was
higher (80%) among patients who initially started with neu-
trophil counts below 1.0 × 109/L that did not rise duringr. 2 0 1 5;3 7(1):28–33
the ﬁrst week of infection compared to the mortality rates
(27%) seen in patients whose neutrophil counts rose above
10.0 × 109/L.21
Hematopoietic growth-stimulating factors are a class of
cytokines that regulate proliferation, differentiation, and func-
tions of hematopoietic cells. G-CSF regulates neutrophil
production.24 The administration of G-CSF to humans results
in a dose-dependent increase in circulating neutrophils.24
In this study, a signiﬁcant reduction in the incidence of FN
using ﬁlgrastim was not found, contrary to what was expected
according to the literature.9,10 This result may be due to the
small sample size. Most of the episodes (77%) were treated
using ﬁlgrastim. This result should be re-analyzed with more
episodes.
The protocol was not adequately followed in every case.
Although this may represent a limitation when interpreting
the ﬁndings of this study, detecting these kinds of failures is
important in order for them to be corrected.
This study emphasizes the high isolation rates of
microbiological agents, especially GNB resistant to
piperacillin/tazobactam, which constitute the front-line
antibiotics in our protocol. The early need of escalation to
carbapenems raises the question as to whether these should
be the front-line treatment for high-risk neutropenia patients
in our service. Moreover, this is a big step as carbapenems are
at the top of the antibiotic option list and when used as ﬁrst-
line treatment, many  problems with resistant strains would
probably arise. As alternatives to carbapenem, a combination
of piperacillin–tazobactam and amikacin may be an effective
empirical therapeutic option for patients with neutropenic
fever who are at high risk of developing bacteremia with
ESBL-producing pathogens.
We  believe that a larger study should be conducted before
making a ﬁnal decision because, although the present work
represents one year’s experience of the evolution of high-risk
neutropenia at a university hospital, the number of the ana-
lyzed episodes is too small to conclude that our front-line
antibiotic option is not suitable.
Conclusions
In this work we observed a high isolation rate of microbio-
logical agents in FN episodes; this was statistically associated
with higher mortality. Bacteremia was the most common
microbiological isolate identiﬁed with a predominance of
GNB, particularly MR. Risk factors for FN were duration and
severity of neutropenia and the isolation of a microbiolog-
ical agent, and the presence of alarm signs was associated
with poor outcomes. The high rate of GNB resistant to
piperacillin/tazobactam, the front-line antibiotics in our pro-
tocol, and the early need to escalate to carbapenems raises
the question as to whether it is necessary to change our
antibiotic treatment protocol for high-risk neutropenia. Fur-
ther prospective studies with a larger number of patients and
episodes of FN should be conducted to conﬁrm these results.Conﬂicts  of  interest
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